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Abstract
The genus Mycobacterium contains many pathogenic bacteria that are known to cause
serious diseases in humans. One of the most well-known of these bacteria is Mycobacterium
tuberculosis, or Mtb, which is the causative agent of tuberculosis. It infects nearly one-third of
the world’s population and kills 1.4 million people annually. Another important mycobacterial
pathogen is Mycobacterium abscessus, or Mabs, which causes respiratory infections in cystic
fibrosis patients. One of the biggest difficulties in combating these pathogens is the lack of
effective diagnostics, as current strategies hold many pitfalls and can be unreliable. One common
method used is sputum smear microscopy which involves acid fast staining of the bacteria
present in a patient’s sputum. This method of detection fails to detect more than 50% of
infections and is unable to differentiate between species of mycobacterium.

This project

introduces a novel method of mycobacterial diagnostics using binary deoxyribozymes
(DNAzymes). Binary DNAzymes recognize bacteria-specific nucleic acid sequences and bind to
them, forming a catalytic core which cleaves a substrate molecule. This cleavage separates a
quencher molecule from a fluorophore, which results in a fluorescent output. This flexible assay
platform has great potential for the detection of Mtb or Mabs. Our data shows the specificity of
the DNAzymes allowing for a differential diagnosis of various species of Mycobacteria. It also
shows the limit of detection of this technology and its additional utility in molecular typing of
Mtb clinical isolates as well as drug resistance characterization. This multipurpose tool can
contribute to disease management in multiple ways.
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Introduction
Pathogenic Mycobacteria
Mycobacterium tuberculosis
The genus Mycobacterium contains many pathogenic bacteria that are known to cause
serious diseases in humans. One of the most well-known of these bacteria is Mycobacterium
tuberculosis (Mtb), which is the causative agent of tuberculosis (TB). Mtb infects nearly onethird of the world’s population and kills 1.4 million people annually [1]. Although Mtb was first
identified as the causative agent of TB in 1893 by Robert Koch, Mtb-human interactions date
back to ancient Egypt and even earlier [2, 3].
Mtb is an acid-fast staining gram-positive bacillus, due to its cell wall’s ability to take up
a positively charged dye. This characteristic is indicative of the molecular structure of the cell
wall, which is composed primarily of mycolic acid and mycolic acid derivatives [4]. These lipid
chains vary in size, ranging from 60 to 90 carbons long [5]. The specific lipids may vary
between different species in the Mycobacterium genus [4]. These long chain fatty acids can
elicit an immune response in a mouse animal model, indicating their recognition as a PAMP, or
Pathogen Associated Molecular Pattern, by the host immune system [6]. The mycolic acid along
with the LPS layers form an envelope which protects the bacteria from host defenses such as
degradative enzymes by forming a permeability barrier and free radicals via its cycloproponated
mycolic acid residues [7].
Mtb is transmitted via aerosolized droplets produced when an infected individual coughs
and expels the bacteria into the environment. Transmission is accomplished when the bacteria is
taken up into a host’s airways and into the lungs where it is internalized by alveolar macrophages
1

into a phagosome [8]. While in the phagosome the bacteria secrete effector proteins which
manipulate the phagosome morphology and recruitment of host proteins involved in vesicle
trafficking. This prevents fusion of the lysosome, allowing the bacteria to survive within the
phagosome and avoid both acid exposure and hydrolytic enzymes [9]. In the case of active TB
disease, which only occurs in 5 – 10% of Mtb infections, the bacteria are able to multiply
unchecked within the macrophage and eventually cause cell necrosis and tissue damage [10]. It
is from this point that the bacteria may spread into the capillaries of the lungs and move
systemically throughout the host. Transmission is accomplished due to the coughing response to
the necrosis within the lungs [8].
The hallmark of a pulmonary TB infection is the presence of a granuloma, a tumor-like
walled off nodule containing infected macrophages, neutrophils, and dendritic cells [8]. Within
the granuloma, the Mtb are located within the macrophages directly within the center of the
granuloma [11]. These infected cells are surrounded by abnormal immune cells such as giant
multinucleated cells and fat containing “foamy macrophages [12].”

The formation of a

granuloma may be an innate immune response to prevent transmission, however current theories
exist that the granuloma formation is evolutionarily beneficial to the bacteria by offering both
protection and nutrients [13]. Mtb within the granuloma are dormant, replicating infrequently
and become highly drug resistant via intrinsic biochemical mechanisms such as efflux pumps [8,
14]. About 90% of those infected with Mtb do not display symptoms immediately and are
referred to as having a latent TB infection (LTBI). In a LTBI, Mtb growth is restrained by
activated macrophages, limiting their ability to spread. An acute production of T-cells is seen at
the peripheral lymph nodes, however production of naïve T cells decline during the chronic
2

infection due to inefficient T cell priming [15].

Th1 T-cells produced aid in preventing

reactivation of the granuloma via the production of cytokines, however research suggest some
cytokines may activate Mtb dormancy genes [16]. LTBI can remain asymptomatic for years or in
5-10% of the cases can reactivate to produce a symptomatic disease. Some research suggests
now that the recruited neutrophils may play a role in the progression of latent to active Tb
infection, causing necrotic cell death of the macrophages within the granuloma containing the
Mtb [8].

This results in caseous necrosis of the granuloma, which facilitates escape and

transmission of the bacteria and allows the cycle to repeat [8, 14] .
Mycobacterium abscessus
Another pathogenic member of the Mycobacterium genus is Mycobacterium abscessus
(Mabs). Mabs is a rapidly growing acid-fast gram-positive rod. Mabs acid-fast properties,
similar to Mtb, are due to the high concentration of mycolic acid present in its cell wall [4].
Mabs was first described in 1953 after it was identified from an abscess in a patients knee, and
was originally classified as a subspecies of M. chelonae [17]. In 1992 genomic analysis and
hybridization studies allowed the determination that Mabs is sufficiently distinct enough from
Mycobacterium chelonae to warrant reclassification as a distinct species [18].
Mabs infections are commonly seen in patients who are immunocompromised. Mabs has
therefore been noted as a common cause of hospital borne infections in a patient post-surgery
[19-21]. Mabs infections can be pulmonary, looking remarkably similar to a Mtb infection [22].
Patients with cystic fibrosis are at a significantly higher risk of developing a pulmonary infection
from Mabs than the general public [23]. Studies estimate that 5-12% of all CF patients are
infected with Mabs, with that number on the rise [22, 24, 25]. Mabs infections can also be
3

extrapulmonary and can occur anywhere on the host, including the eye, with a majority reported
as subcutaneous [26]. An extrapulmonary Mabs infection can commonly produce an abscess, or
walled off fluid filled sac, giving Mycobacterium abscessus its namesake [27].

Although

originally considered rare Mabs infections are now 10 times more common in the USA than Mtb
infections [19, 28].
Drug Resistance
Treatment of both Mtb and Mabs involve the usage of different multi-drug cocktails
which are taken for 6-9 months [29, 30]. Mabs is extremely difficult to treat due to intrinsic drug
resistances to a variety of treatment options, including the drugs used to treat Mtb. The effects of
its lipid envelope, degradative enzymes and efflux pumps, result in an even longer antibiotic
treatment regimen than that for Mtb [31, 32]. Mtb has been shown to express a variety of
mechanisms to survive drug treatment. Dormant bacteria may be signaled from a variety of
stress conditions such as the decrease in pH or hypoxia inside of the phagosome to begin
transcription of essential genes [33]. This results in the upregulation of multiple efflux pumps
and drug inactivating enzymes which confer drug resistance to several antibiotic compounds
such as tetracycline [34-37]. The complex regulons which control these efflux pumps are
currently new targets of antimicrobial research and development.
Treatment of Mtb has become increasingly difficult due to the emergence of drug
resistance mutations in the Mtb genome. It has been shown that SNP’s, or single nucleotide
polymorphisms, can alter a drug target and prevent antimicrobials from inhibiting their target’s
function. Mtb can acquire multiple drug resistance mutations, resulting in Multi-Drug Resistant
Tuberculosis (MDR-TB). A Mtb infection will be diagnosed as MDR-TB if it is shown that the
4

bacteria has resistance to both isoniazid and rifampin, two first line treatment options [38].
Rifampin (Rif) targets the β subunit of the RNA polymerase, encoded by the rpoB gene [39]. It
has been shown that the rpoB gene contains an 81 base pair hotspot region which has a
significantly higher rate of mutations in Rif-resistant strains of Mtb, indicating a genetic target
for drug-mediated artificial selection [40]. Mutations in both the 526 and 531 codons have
commonly been shown to confer drug resistance, altering the Rif binding site on the β subunit
[41].
Isoniazid (Inh) is another first line treatment option for Mtb [38]. Isoniazid binds the
product of the inhA gene, a long-chain enoyl-acyl carrier protein reductase involved in
elongation of the mycolic acid fatty chains [42, 43].

Mutations in the inhA gene confer

resistance to Inh by preventing binding in the active site, however the occurrence of a mutation
in the ORF (open reading frame) is not commonly the case [44-46]. Mutations within the inhA
promoter also result in resistance due to increased production of the protein product, resulting in
low-level resistance to clinically used Inh concentrations [47]. Missense mutations in the katG
gene, a gene which encodes a catalase-peroxidase enzyme, also confer Inh resistance [45, 48-50].
The KatG protein activates Inh by coupling it to NAD(+)/ NADH, forming an active product.
Mutations in KatG prevent this activity, however both catalase and peroxidase activity is
maintained indicating a more complex relationship between KatG and Inh than originally
hypothesized [49, 51].
Extensively drug resistant TB (XDR-TB) is a subtype of MDR-TB where the bacteria are
additionally resistant to a fluoroquinolone (FQ) as well as an injectable second line drug.
Fluoroquinolones bind to the gyrase and topoisomerase enzymes used to move the replication
5

fork forward during DNA replication and relieve tension by unwinding the DNA [52]. The
binding of FQs prevents DNA replication and damages the genome, eliciting an SOS cellular
response and the generation of oxygen radicals resulting in cell death [53]. Resistance to FQs is
due to mutations in the gyrA gene or the gyrB gene, both of which encode gyrase enzymes in
Mtb [54]. These mutations change the amino acid sequence in the FQ binding site, dramatically
increasing its minimum inhibitory concentration [55].
Diagnostics and Drug Resistance Characterization
Before the development of molecular techniques, a pathogenic mycobacterial infection
was diagnosed based on sputum smear microscopy [56].

This technique is quick and

inexpensive, which is why it is still currently utilized as a Point of Care (POC) diagnostic. An
infected patient is required to provide a sputum sample, which is then processed to isolate the
bacteria. The sample is then stained with carbol-fuchsin and counterstained with methylene
blue. Due to the mycolic acid component of the cell wall, the carbol-fuchsin will be retained by
the mycobacterium, resulting in a red appearance. This method of staining is also referred to as
the Ziehl-Neelsen stain, and can detect a minimum of 5,000 to 10,000 bacilli per milliliter [57,
58]. Acid fast staining has been the gold standard for detecting Mtb for over 100 years due to its
cost effectiveness. Unfortunately, this technique is highly ineffective at detecting an infection,
failing to do so almost 50% of the time [59]. Sensitive detection is even more problematic in
children and patients that are co-infected with HIV [60, 61].

This is likely due to the inability

to obtain a large enough sputum sample to visualize the bacteria. Higher occurrences of extra
pulmonary TB in immunocompromised patients also make diagnostics using sputum more
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difficult [60]. The Ziehl-Neelsen stain is also unable to differentiate between different species in
the Mycobacterium genus.
Another non-molecular method of diagnosing pathogenic mycobacteria is by using an
apparatus known as a Mycobacteria growth indicator tube (or MGIT). The MGIT tube contains
Middlebrook 7H9 Broth, a liquid growth medium containing the essential composition for
Mycobacterial growth [62]. After a patient’s sputum is processed, the sample is placed in the
MGIT tube. If mycobacteria are present then they will begin to grow in the tube and respire
using the dissolved oxygen. The depletion of oxygen in the tube results in the activation of a
fluorescent compound and therefore detection. The increasing cases of drug resistant Mtb has
resulted in resistance characterization becoming a necessary and integral part of both treatment
and diagnostics [63]. Adding various drugs such as Rif and Inh to the MGIT allow this test to be
utilized for drug susceptibility testing [38].
Another common technique used to diagnose Mtb is the Mantoux test, also known as the
PPD (Purified Protein Derivative) skin test or the Tuberculin skin test. This test relies on
analyzing the body’s response to a small injection containing tuberculin, a protein extract from
Mtb [64]. The actual make-up of PPD may vary and is known to contain many different
antigens. After the tuberculin has been injected, the size of the raised skin is measured in
millimeters. A positive result indicates the host has already mounted an immune response to Mtb
or an Mtb like antigen. The criteria for diagnostics may vary between patients, with specific size
intervals and additional risk factors of the patient contributing to the analysis [64]. A chest Xray usually follows to determine if an active disease state is present.
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The PPD skin test, which does not indicate an active infection but only the presence of a
secondary immune response, is known to cross react with patients who have previously been
vaccinated with the BCG vaccine. The BCG, or Bacille de Calmette et Guérin, vaccine is made
of an attenuated strain of Mycobacterium bovis, a mycobacterium which causes TB-like
symptoms in cattle. Mycobacterium bovis contains enough similarities with Mtb to elicit an
immune response, however the efficacy of the vaccine is anywhere from 0 – 80%, which is why
the vaccine is not widely utilized in the United States (however it is used widely around other
parts of the world) [65]. Due to the antigenic similarities between Tuberculin and the BCG
vaccine, those previously vaccinated will elicit a more powerful immune response, resulting in a
false positive. False positives may also result from an infection by other members of the
Mycobacterium genus, such as those found in the environment [66, 67].
Modern molecular biology has opened the door for new methods of diagnostics of
pathogenic mycobacteria. Nucleic Acid Amplification Tests (or NAATs), rely on the usage of
polymerase chain reaction (PCR) to amplify specific sequences of DNA derived from the
bacteria [68]. Common targets for identification of the bacteria are the highly conserved and
species specific 16S and 23S rRNA of the ribosome [69]. The amplicon may then be sequenced
for diagnosis or hybridized to a molecular probe [70]. A hybridization probe is a synthetic
oligonucleotide containing a sequence that is complimentary to the target sequence. Binding of
the molecular beacon may separate a fluorophore from a quencher molecule, resulting in a
fluorescent signal. By targeting the genes responsible for drug resistances, molecular probes are
also able to characterize the drug resistances of the bacteria [71]. This can also be determined
via DNA sequencing. New advancement in molecular diagnostics has allowed the process to be
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miniaturized by using oligonucleotides covalently linked to a membrane or a microchip [72].
This technique is highly effective and only requires a small amount of DNA.
A commercially available diagnostics technique that implements NAATs is the Cepheid
Gene Xpert which can both detect Mtb and Rif drug resistance.

The WHO has financed

promotion of the Gene Xpert, subsidizing the costs of the instrument and assay reagents in
resource poor countries with high endemic TB rates. This technology takes two hours to both
analyze the presence of Mtb and characterize Rif drug resistance [73, 74]. Unprocessed sputum
is sonicated to lyse the bacteria and the nucleic acid is purified and concentrated. The nucleic
acid is then PCR amplified and hybridized to probes which provide species identification along
with probes which target the rpoB gene. Gene Xpert’s sensitivity was determined via a LOD
study to be 131 CFU per ml and can accurately differentiate against non-tuberculosis
mycobacteria by targeting nonhomologous regions of the rpoB gene [73]. The rpoB gene is
targeted by 5 separate molecular beacons, each requiring their own unique color to both diagnose
and characterize Mtb [75]. Unfortunately it seems this technology has only proved cost effective
in reference centers, requiring expensive equipment and reagents. The requirement of electricity
and trained personnel makes this technique difficult to implement into a Point of Care diagnostic
setting [76].
Mtb Genetic Diversity and Classification
Molecular tools for genetic characterization of Mtb revealed lineage specific differences,
allowing populations to be sub-classified into both lineages and strains [77]. The Mtb lineages
can be classified as either modern or ancient, with lineages 2-4 considered modern. This
classification is based on the presence or absence of TbD1, which is absent in modern strains
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[78].

There are 7 Mtb lineages that can infect humans, each of which are associated with

different geographical regions (see table 1). The seven lineages can be further divided into
different strains, each of which has a unique genetic makeup. The two strains of Mtb that are
most common in research lab settings are H37Rv and CDC1551.
Table 1: Mtb Lineages

Lineage Geographic Classification

Because the different strains are over 90%

1

Indo-Oceanic

genetically identical, it was originally believed that

2

East-Asian

there were no significant differences between them.

3

East- African – Indian

Recent evidence however suggests that the different

4

Euro-American

5

West- Africa

6

West- Africa

7

Ethiopia

Mtb lineages differ in virulence [77].

Unlike many

other pathogenic bacteria, Mtb does not possess any
toxin mechanisms; therefore virulence is often directly
equated to transmission. It has also been seen that a
lower immunological response is correlated to higher

bacterial populations in the host, resulting in higher transmission[77].

Modern strains are

commonly associated with a delayed inflammatory response and are therefore seen to exhibit a
higher level of transmission along with differences in global gene expression and macrophage
survival [79, 80].

These modern lineages are also associated with a higher likelihood of

progression to an active disease state and are seen more globally than the ancient strains,
suggesting that the delayed inflammatory response may be associated for the globalization of the
lineages. Between the modern lineages, lineage 2 is seen to have the highest virulence along
with the highest occurrences of de novo drug resistances [81]. Ford et al. have shown that this
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may be a result of the higher mutation rate seen within lineage 2 [82]. These phenotypic
differences illustrate the effect in both the disease progression and treatment that the Mtb’s
genetic variability has on an infection.
Mtb lineage and strain identification is useful to track Mtb’s virulence, evolution, and for
epidemiological studies [83, 84]. The spread of Mtb can be mapped out according to lineage,
allowing determination of population based infection patterns. Analysis of the Mtb genome in
seals suggests a similarity between the murine strain and the strains seen in the Americas,
suggesting that Mtb may have jumped from seals to humans [85]. On a micro-population basis,
analysis of the different lineages and strains can elucidate infection patterns allowing the
determination of transmission of Mtb between individual patients.

It is also useful in the

determination of nosocomial infections along with the origin of MDR/XDR-TB, allowing
researchers to analyze whether a patient infected with Mtb acquired the infection within the
hospital or before entering it [86]. Finally, strain typing can be used in conjunction with drug
resistance determination in order to determine the prevalence of de novo mutations conferring
drug resistance. This can be used to help determine if drug resistant Mtb strains in health-care
settings are due to internal transmission of the MDR-TB or due to evolution of resistance during
treatment selection.
Strain Typing Methods
A variety of molecular techniques have been used to classify and type Mtb, analyzing
genetic markers such as SNPs, insertions, repeats and deletions. The first molecular technique
used to analyze Mtb was restriction fragment length polymorphism (RFLP) typing.

This

technique relies on a difference in copy numbers and location of a genomic insertion sequence
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(IS6110) in the Mtb genome and was originally hailed as the “gold standard” of strain typing
[87]. RFLP involves the digestion of the chromosomal DNA with an endonuclease, resulting in
the production of many fragments of variable lengths. The digested DNA is then separated on an
agarose gel via electrophoresis, where DNA fragments of larger sizes migrate slower than those
of smaller sizes. The gel is then blotted onto a nylon membrane which absorbs the DNA and
retains their relative positioning on the gel. The IS6110 insertion sequence is then detected using
fluorescent or radioactive probes and imaged. This allows for determination of repeat sequences
relative to the migration pattern of the DNA band and therefore characterization of the strains
[88, 89]. Unfortunately this technique requires large amount of DNA and has a propensity of
contamination, illustrating the need of newer technology.
Only a few years later, the need for more effective molecular techniques led the way to
PCR-based methods of analysis being developed. By utilizing primers specific to sequences
found only in Mtb, the specificity of the PCR based characterization methods were determined to
be 100% [77]. Two methods of PCR based analysis that have become common in strain
identification include Spoligotyping and MIRU typing. Spoligotyping, or spacer oligotyping,
involves PCR amplification of 43 unique regions located between direct repeats in the Clustered
Regularly Interspaced Short Palindromic Repeat region (CRISPRs) [90].

This results in the

amplification of a large number of fragments which may vary in size. The amplified fragments
are then hybridized to a membrane which has the corresponding oligonucleotides covalently
bonded. The hybridization pattern differs from each lineage and strain of Mtb, allowing for
effective strain identification [88]. This technique can be used in conjunction with RFLP typing
or independently [91].
12

MIRU typing differs from spoligotyping in the target of the PCR amplification. MIRU
typing is accomplished via the PCR amplification of MIRUs, or Mycobacterial Interspersed
Repetitive Units [92]. These MIRU’s are found within the Mtb genome and are reminiscent of
human Variable Number Tandem Repeats (VNTRs) [93]. The MIRUs of interest are amplified
via PCR and separated using gel electrophoresis. The gel is then stained and the size of the band
is determined via comparison to a molecular marker of known sizes [89]. Results from both
MIRU typing and Spoligotyping can be compared to a known culture or compared to an online
database, allowing for strain and lineage determination [94, 95].

Unfortunately, identical

patterns between strains can result from convergent evolution which would make strain
identification and evolutionary determination nearly impossible [96].
Another method of characterization of the Mtb strains and lineage is the determination of
Large Sequence Polymorphisms (LSPs), also referred to as Regions of Difference (RDs). This
method of characterization relies on amplification of a region of the Mtb genome containing a
large deletion, followed by gel electrophoresis and detection using probe hybridization [97].
Because large genomic deletions are irreversible, LSP analysis is very useful for determination
of a lineages evolutionary history [98].
Spoligotyping, MIRU typing and LSP analysis have revealed a high level of variability
within lineages and strains of Mtb, along with similarities between strains and lineages which
may have resulted from independent evolutionary events. This has resulted in the use of whole
genome sequencing in determining the phylogenetic lineage of an Mtb strain [99, 100]. Whole
genome sequencing was first accomplished via the shotgun sequencing method, where the entire
genome is randomly cleaved and each fragment in inserted into a plasmid and transformed into
13

competent cells. The individual fragments were then sequenced and assembled using a variety
of computer programs [101]. Whole genome analysis not only showed LSP but also elucidated a
variety of important SNPs, or single nucleotide polymorphisms. These SNPs are differences in a
single nucleotide between lineages or strains of Mtb [102, 103]. Recently an algorithm has been
developed which allows lineage determination based on the sequencing of only a few genes,
relying totally on the determination of a few SNPs in order to classify a strain of Mtb [104].
Binary Deoxyribozymes
One form of molecular diagnostics and characterization that has not been applied to Mtb
or Mabs before is a binary deoxyribozyme, or DNAzyme. DNAzymes are catalytic strands of
DNA based on naturally occurring ribozymes which, in the presence of a metal cofactor, have
been shown to facilitate the cleavage of an RNA or RNA/DNA phosphodiester bond [105].
Variations exist however which have peroxidase like activity or silence genes via mRNA
cleavage [106, 107]. One of the most studied DNAzymes is the 10-23 DNAzyme which cleaves
an RNA molecule between a purine and pyrimidine [108]. The region of the DNAzyme which is
enzymatically active is referred to as the catalytic core (see Figure 1a). The deoxyribozyme was
first developed by Breaker and Joyce after selective amplification of random nucleotides [109,
110].

The use of a peptide bound oligonucleotide allowed for the in vitro selection of

catalytically active DNA sequences [111].
UCF professor and collaborator Dr. Dmitry Kolpashchikov, as well as others, have
shown that a variety of modifications can transform the DNAzyme into an assay which can
detect the presence of specific nucleic acid sequences. By splitting the catalytic core of a
deoxyribozyme, the DNAzyme loses its catalytic activity. However reformation of the core
14

between the two strands can restore the molecules enzymatic abilities (see Figure 1b) [112, 113].
The DNAzyme can also be altered so that the transition from inactive to active state only occurs
in the presence of a specific analyte sequence. The DNAzyme can then cleave a substrate
molecule, which may vary for fluorescent (see figure 1c) or visual output. This reaction can be
measured by a plate reader or spectrophotometer [114, 115].

Astonishingly, the binary

DNAzyme assay has been shown to be specific enough to differentiate between two targets that
differ by only a single SNP [116, 117].

Figure 1: Development of the Binary Deoxyribozyme. 1a) A standard Deoxyribozyme consists of a catalytic core
and substrate binding arms. 1b) a Binary Deoxyribozyme consists of 2 separate strands each with analyte binding
arms complimentary to a target sequence. 1c) When bound to a target analyte, the catalytic core is able to be
reformed, allowing binding of the substrate binding arms and cleavage of a substrate molecule to release a florescent
output.

Designing a binary DNAzyme sensor assay first requires basic knowledge of the binary
DNAzyme structure. A fully assembled binary DNAzyme consists of three primary structures,
the analyte binding arms, the catalytic core, and the substrate binding arms [116]. Each sensor
strand therefore contains one analyte binding arm, one substrate binding arm and one half of the
catalytic core (see figure 2).
The substrate binding arm sequence is designed to be complimentary to the sequence of
the substrate molecule. The substrate molecule for the fluorescent assay is a synthetic DNA-
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RNA hybrid oligonucleotide analyte, containing a ribonucleotide directly in the center of the
molecule allowing for cleavage [114]. Other modifications include a fluorophore and a quencher
at the 5’ and 3’ of the molecule respectively [114]. The specific substrate utilized is known as
Mzf Substrate and consists of a FAM fluorophore and BHQ quencher.
The catalytic core of the DNAzyme is responsible for facilitating the actual enzymatic
reaction the molecule catalyzes. Variants of the sequence of the catalytic core exist, resulting in
a higher or lower catalytic rate [105]. The use of different catalytic cores also alters the chemical
reactions that the DNAzyme can perform such as bond cleavage or peroxidase-like activity
[118].
Similar to the design of the substrate binding arm, the analyte binding arm is designed to
be complimentary to the target sequence being analyzed, such as sequences found in the rRNA
of Mtb [119].

Designing these arms requires previous knowledge of the sequence being

analyzed, and it is these arms which are redesigned to create a new binary DNAzyme assay.
In a fluorescent binary DNAzyme assay, the complementarity of the analyte and the
analyte binding arms results in both strands hybridizing to the analyte. This consequently leads
to the reformation of the catalytic core and allows the substrate binding arms to bind to the
substrate molecule. The newly functional binary DNAzyme then catalyzes the cleavage of the
substrate molecule which separates the fluorophore and the quencher. This liberated fluorophore
can be quantified as fluorescent units using a plate reader or spectrophotometer. The full
structure of a binary DNAzyme complexed with its matched analyte is shown in below.
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Figure 2: Structure of a Binary DNAzyme. All binary DNAzymes consist of substrate binding arms which have a
complimentary sequence to the substrate molecule, a catalytic core which catalyzes cleavage of the substrate
molecule, and analyte binding arms which are complimentary in sequence to a target analyte. Designing a new
sensor pair only requires redesigning the analyte binding arms.

The binary DNAzyme has many advantages over conventional molecular diagnostic
techniques. Because substrate molecule is universal between all fluorescent DNAzyme assays,
designing a new assay does not require redesigning or reordering the substrate molecule.
Altering the probes for a totally new assay simply requires redesigning the two strands which
bind to the new target analyte [120]. These sensors have been implemented in the detection of
bacterial nucleic acids, however they can be redesigned to detect other nucleic acid based
infectious agents such as viruses [120]. Furthermore, detection of human SNPs with binary
DNAzymes is also possible [121]. Some other advantages of the DNAzyme sensor assay are
that they do not require trained personnel, and lack the requirement of an amplification step
when targeting genes present in high copy number.
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Methods and Materials
Binary DNAzyme Assay
General Binary DNAzyme Assay
After designing a binary DNAzyme, the sensors are tested with a matched and
mismatched analyte to assure their correct design. Each fluorescent assay also has two intrinsic
controls built in to analyze both stability of the substrate molecule and the background signal
produced from unbound sensor strands. The first control consists of 200nM of the Mzf substrate
molecule in Col buffer. Col buffer consists of 50Mm HEPES, 50mM MgCl2, 20mM KCl,
120mM NaCl, 0.03% Triton X-100 and 1% DMSO. This buffer supplies the DNAzyme with all
the essential cations required for catalytic function. Correct concentration of both the substrate
and ions within the Col buffer is insured by utilizing 30μl of a 2X Col buffer, adding the
substrate molecule, and diluting the sample with dH2O up to the standard total reaction volume
of 60μl.
Next, a master mix is made consisting of the two sensor strands, substrate, Col 2X buffer,
and dH2O. Total volume necessary for each test sample along with a background sample and
one additional sample is first determined (ReactionVolTotal). The master mix consists of Col 2X
buffer at a volume of one half this total reaction volume (ReactionVolTotal /2). Each sensor strand
is then added to the master mix at a concentration of 15nM along with the substrate molecule at a
concentration of 200nM. To determine dH2O added to the master mix, the total volume is
multiplied by .75 to give the total master mix volume (MasterMixVol = .75 x ReactionVolTotal).
dH2O is then added to the master mix to bring to total volume up to this calculated value.
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Each sample tube then receives 45μl of the Master mix. 15μl of dH2O is added to the
background tube, forming the second internal standard for comparison.

The sample tubes

receive the matched or mismatched analyte at a concentration of 1nM and dH2O is then added to
bring the total volume of the tubes up to 60μl.
The samples along with both the substrate and background control are placed in a 384
well black bottom plate and incubated at 54°C for 1 hour in a hybridization oven.

The

fluorescent intensity is then measured in a Synergy 4 Biotek Plate Reader. Detection using the
plate reader has been optimized, with best results using Filter Based detection with excitation
and emission wavelengths of 485nm and 520nm respectively and a read height of 1mm. Each
fluorescent signal is then divided by the signal of the background control, allowing the
measurements to be interpreted as a signal to background ratio (S/B).
Specificity and Limit of Detection
Assays were designed for Mabs with comparable TB sensors being tested by other
members of the lab. Two varieties of the standard binary DNAzyme assay include a specificity
study along with a limit of detection study. The goal of the specificity study goal is to compare
the signal to background ratio obtained by the matched analyte with that of the mismatched
analyte in the form of a specificity value. Three different types of analyte were routinely tested:
synthetic oligonucleotides, total RNA, and PCR amplicons. 1nM of synthetic analyte is utilized
while 200ng of total RNA is used. PCR amplicon concentration is difficult to determine without
purifying out any residual dNTPs, so 15μl of the PCR product is routinely utilized. When testing
total RNA as analyte, an additional binary DNAzyme assay is commonly performed using
sensors complimentary for the sequence of the mismatched analyte to assure integrity of the
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RNA. The specificity study is performed in triplicate in order to generate averages along with
standard deviation.
The limit of detection (LOD) study utilizes many samples of serial dilution of matched
analyte in order to form a linear graph which correlates S/B ratios with target analyte
concentration. The target analyte is serial diluted in regular intervals to produce many samples
of decreasing concentration. A DNAzyme assay is then performed in triplicate on the various
analyte samples, and a scatterplot is generated comparing S/B ratio (Y) with analyte
concentration (X). The LOD value is the concentration of analyte which produces a signal to
background ratio equal to that of the background sample (no analyte) plus three times the
background samples standard deviation [122]. The LOD test can be performed on both synthetic
analytes as well as RNA.
Visual Identification
Visual detection is accomplished using a second DNAzyme, known as IPDZ, as the
substrate molecule in what is known as a DNAzyme cascade [118]. The binary DNAzyme
facilitates cleavage of a ribonucleotide separating an inhibitory component of the second
DNAzyme, liberating the catalytic PDz fragment [123]. This DNAzyme folds into a GQuadruplex formation and, in the presence of a hemin cofactor, has peroxidase activity which
can be detected via the oxidation of the colorimetric substrate DAB in the presence of H2O2 (see
figure 4). The resulting molecule changes the solution from clear to brown, allowing visual
detection or absorbance measurement [117, 123].
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Figure 3: Visual Reaction Cascade. A) A visual binary DNAzyme assay requires the two binary DNAzyme
strands, each consisting of an analyte binding arm, substrate binding arm, and half of a catalytic core. The assay
also requires an inhibited peroxidase like DNAzyme (IPDz). B) In the presence of a specific analyte, the binary
DNAzyme is able to bind and reform the catalytic core, allowing cleavage of the inhibitory fragment from the IPDz
to form PDz. C) Liberated PDz adopts a G-quadruplex like structure and in the presence of hemin can catalyze an
oxidoreductive reaction to produce a colored product.

A visual binary DNAzyme assay consists of the same setup and controls as a fluorescent
binary DNAzyme assay with a few minor alterations. The initial substrate molecule, IPDZ, is
used at a 1μM concentration while each sensor strand is used at 100nM. The assay is then
incubated at 50°C for 1 hour. Afterwards, 2μl of a 1:1 mixture of DAB and hemin at 25μM is
added to each tube followed by 1μl of H2O2. After 30 minutes of incubation at room temperature
the absorbance is measured at 500nm in a spectrophotometer.

Specificity tests were

accomplished utilizing 100nM of analyte.
SNP Analysis
Specific design parameters must be applied to binary DNAzymes intended for the
detection of single SNPS. These sensors are constructed with a long arm and a short arm, with
the short arm containing the discriminatory SNP. This methodology allows the strand containing
the long arm to be utilized for both detection of both wild type and mutant variations. Because
the SNP-containing arm is shorter than the nondiscriminatory arm its lower annealing
temperature allows for more sensitive mismatch discrimination [117].
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Our approach to DNAzyme-based SNP detection uses an algorithm for strain typing
developed by Homolka et al. that defined the minimal number of SNPs required for high
resolution lineage assignment identification (see figure 3) [104]. As proof-of-principle for the
utility of our technology for strain typing we designed sensors to analyze the GC mutation of
the 455th residue of the Rv0557 gene which allows the determination of Haarlem vs.
NonHaarlem lineage (See appendix).

Figure 4: Strain Typing SNPs. Homolka et al. were able to determine the minimum number of SNPs needed to be
sequenced in order to effectively characterize strain lineage. This was accomplished computationally after multiple
rounds of whole genome sequencing on different strains of Mtb.

As a proof of principle experiment to characterize drug resistance, we also designed
sensors to detect the most common drug resistance mutations within the rpoB gene, a C526G
mutation which confers Rif resistance (See table).
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Target Amplification
Analysis of SNPs in genes which are present in low copy number requires PCR
amplification in order for efficient detection. PCR amplification of a target sequence requires
two primers which bind both upstream and downstream to the target sequence respectively. The
sequence of the forward primer is identical the sense strand while the reverse primer is the
reverse complement. A standard PCR reaction includes 1μl DNA at approximately 20ng/μl
concentration, 1μl each forward and reverse primers at 100ng/μl concentration, .25μl of Phusion
DNA polymerase at 2000U/ml concentration, 5μl of HF Buffer, 16.25μl of dH2O, and .5μl of
dNTPs at 10mM concentration. The PCR reaction sample is then placed into a Philisa thermal
cycler which can quickly cycle through various temperatures, allowing the DNA to denature, the
primers to anneal to the separated DNA, and the polymerase to extend the primers and form a
new strand of DNA. Initially the sample is heated to 98°C for 3 minutes, followed by 50 cycles
of 98°C for 10 seconds, 67°C for 15 seconds, and 72°C for 10 seconds. The temperature is then
held at 72°C for 30 seconds and cooled to room temperature. In order to determine drug
resistance, PCR primers were designed and utilized for the rpoB gene in an effort to characterize
Rif resistance (see appendix).
It has been hypothesized that a binary DNAzyme is more sensitive utilizing single
stranded DNA (ssDNA) and an analyte compared to double stranded DNA due to needing to
compete with the antisense strand for hybridization. One method of generating ssDNA is
asymmetric PCR. In asymmetric PCR, one primer is decreased in concentration significantly
(1:40). This results in exponential increase in DNA during the initial cycles until the limiting
primer runs out. After depleting the limiting primer, extension of only the excess primer causes
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the linear production of ssDNA. LATE-PCR, OR Linear After The Exponential PCR, accounts
for the fact that decreasing the concentration of one of the primers decreases the effective
annealing temperature, leading to ineffective amplification [124]. LATE-PCR addresses this
problem via altered design of the limiting primer, where it is extended by 2 to 3 nucleotides.
This raises the effective annealing temperature of the limiting primer, allowing for an increase in
output [125]. Both LATE-PCR and symmetric PCR primers were designed for the amplification
of a small fragment of the 23S rRNA gene in Mtb (See Appendix).
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Results and Discussion
Mabs Detection
Fluorescent Detection
Fluorescent sensors to detect Mabs were developed which targeted regions of the 23S
rRNA, 16S rRNA and tmRNA genes [126]. The sequences selected based upon multiple sequence
alignments were homologous among different strains of Mabs, allowing detection of all strains.
The regions selected however were variable between different species of Mycobacterium,
allowing for efficient species differentiation from Mycobacterium tuberculosis complex.
Because the genes chosen are present in high copy number, PCR amplification was not needed.
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Figure 5: Mabs 23S rRNA, tmRNA and 16S rRNA Limit of Detection using Synthetic Analyte. A) B) and C)
represent signal to background ratio of fluorescence at various concentrations of synthetic analyte for Mabs 23S
rRNA, tmRNA and 16S rRNA respectively. The red line represents limit of detection. Each graph represents the
averages of 3 separate experiments.

Limit of detection studies were completed in triplicate using both synthetic analyte and
total RNA using a range of 0.5nM (0.25nM for 23S rRNA) to 0.015625nM for synthetic analyte
and 100ng to 6.25ng for total RNA. The red line indicates the S/B Ratio for the limit of
detection.

The limit of detection using synthetic analyte was determined to be 48.18pM,

51.76pM and 28.54pM for 16S rRNA, 23S rRNA and tmRNA sensors respectively. These
numbers are similar to that of sensors previously designed to detect 16S rRNA and 23S rRNA in
Mtb, indicating effective detection. Limit of detection also indicates quality of the sensors, as the
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analyte concentration used to determine the value is the same, allowing comparison between the
sensors.
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Figure 6: Mabs 23S rRNA, tmRNA and 16S rRNA Limit of Detection using Total RNA. A) B) and C)
represent limit of detection studies utilizing total RNA at various concentrations for Mabs 16S rRNA, 23S rRNA
and tmRNA respectively. The red line represents the limit of detection. Each graph represents the average of 3
independent experiments.

The limit of detection using total RNA was determined to be 4.34ng, 37.42ng and
41.07ng for 16S rRNA, 23S rRNA and tmRNA sensors respectively. The differences in these
values are not able to indicate differences in quality of the sensors, as the limit of detection using
RNA is also influenced by the total copy number in the total RNA. The results of this study
demonstrate the potential to detect mycobacterial RNA directly without the need for
amplification.
In addition to limit of detection, the specificity ratio of the 23S rRNA and tmRNA Mabs
sensors were determined by comparing the S/B of the perfect match analyte (Mabs) with the
mismatch analyte (Mtb).

A high specificity ratio assures that the sensors will be able to

accurately differentiate between different species of Mycobacterium, preventing the possibility
of a false positive.
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Figure 7: Mabs 23S rRNA and tmRNA Specificity using Synthetic Analyte. A) and B) represent specificity of
Mabs 23S rRNA and tmRNA sensors respectively. Sensors were tested in triplicate with synthetic matched (Mabs)
and mismatched (Mtb) analyte.

The specificity ratios of the 23S rRNA and tmRNA sensors using synthetic analyte were
determined to be 5.69 and 3.46 respectively. The matched analyte for the 23S rRNA Mabs
sensors gave a S/B Ratio of 5.69 while the mismatched analyte only produced a signal of 1.04.
The difference in the specificity ratios between the 23S rRNA and the tmRNA sensors is
explained by the lower overall signal the matched analyte produced, with a S/B Ratio of 3.46
compared to 1.25 produced by the mismatched analyte. These results show that our sensors were
accurately able to discriminate against different genetic regions between Mabs and Mtb,
providing the ability to differentiate between the two mycobacteria.
Visual Detection
Visual sensors to detect Mabs which target the 23S rRNA, 16S rRNA and tmRNA genes
were also developed and tested for their limit of detection and specificity ratio. These sensors
were easily designed, utilizing the same analyte binding arms and catalytic core portion as the
fluorescent sensors, and only required altering the substrate binding arms. In order to quantify
the color change due to the colorimetric reaction, absorbance was measured at 500nm. A
positive readout can also be obtained by simply observing a change in color, indicating the
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presence of a matched analyte. The ability to detect this color change by the naked eye is
necessary for POC diagnostics as it eliminates the need for expensive equipment to analyze the
results.
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Figure 8: Mabs 23S rRNA, tmRNA and 16S rRNA Visual Limit of Detection using Synthetic Analyte. A) B)
and C) represent signal to background of absorbance (500nm) using synthetic analyte at various concentrations for
Mabs 16S rRNA, tmRNA, and 23S rRNA respectively. Each graph represents the average of 3 separate
experiments. Visual detection was also confirmed via a color change. The red line represents limit of detection.

Limit of detection studies were completed in triplicate using synthetic analyte at a
concentration range of 10nM to 16pM. The limit of detection was determined to be 946pM,
948pM and 2624pM for 16S rRNA, tmRNA and 23S rRNA visual sensors respectively. This is
not surprising, as the limit of detection of visual sensors are commonly seem to be at least ten
times higher than that of their fluorescent counterpart [123].
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Figure 9: Mabs 23S rRNA and tmRNA Visual Sensors Specificity. A) and B) represent specificity of Mabs
visual 23S rRNA and 16S rRNA sensors respectively. Absorbance (500nm) of each sensor was tested 3
independent times with matched (Mabs) and mismatched (Mtb) synthetic analyte. The difference in specificity was
also observed visually.
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The specificity ratios were experimentally determined in triplicate using synthetic
analyte, with the 23S rRNA and 16S rRNA visual sensors scoring a 2.19 and 2.35 respectively.
The S/B Ratio for the matched analyte of the Mabs 23S rRNA sensors was 2.41 while the S/B
ratio for the mismatched analyte was 1.10. The S/B Ratio for the matched analyte of the Mabs
16S rRNA sensors was 2.00 while the S/B ratio for the mismatched analyte was 0.85. The S/B
Ratios of visual sensors are also commonly seen to be lower than that of fluorescent sensors.
This is due to the lower signal range of visual assay versus fluorescence. S/B Ratios using a
matched analyte on a visual sensor’s typically reaches a maximum of about 2.5.
Amplification
Symmetric vs. LATE-PCR
Analyzing genes present in low copy number requires the use of an application technique.
We compared traditional (symmetric) PCR to LATE-PCR (asymmetric) in order to determine the
most efficient amplification technique for using a binary DNAzyme. LATE-PCR generates
ssDNA due to decreasing the concentration of an extended limiting primer. Primers were
designed to amplify a small fragment of the 23S rRNA gene in Mtb. The PCR products were
then run on an agarose gel and stained with Gel Red to image. The appearance of a second band
in the LATE-PCR sample indicates the production of ssDNA. The PCR product was then
subjected to a binary DNAzyme assay using Mtb 23S rRNA sensors.
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Figure 10: Symmetric vs. LATE-PCR using 23S Mtb rRNA Sensors. 15μl of symmetric PCR and LATE-PCR
product amplifying a fragment of Mtb 23S rRNA was tested using a Mtb 23S rRNA fluorescent sensor.

Surprisingly, the S/B ratio using symmetric PCR compared to LATE-PCR was nearly
identical, which was contrary to our working hypothesis. Figure 11 represents the data from a
single repetition; however the results were replicated with similar results in multiple independent
experiments. The reason the generation of ssDNA does not affect the S/B ratio is still unknown,
although one possible explanation is because the generation of ssDNA is linear, the total
concentration of amplicon, single and double stranded, is significantly less than that of
symmetric PCR. Another explanation could be that due the small size of the amplicon, the
binary DNAzyme sensors are able to efficiently outcompete the antisense strand from binding to
the target. The excess concentration of the sensors may also increase the signal when using a
PCR amplicon as an analyte.
Cycle Optimization
In order to determine optimal cycle number, primers were designed and used to amplify a
250 base pair fragment of the rpoB gene of wild type Mtb using 30x, 40x, and 50x cycles. This
was confirmed using agarose gel electrophoresis. A binary DNAzyme assay using rpoB wild
type sensors was then completed to determine how cycle number affects S/B ratio.
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Figure 11: rpoB Wild Type Sensors on Determining Optimum PCR Cycle Number. 15μl of standard PCR
product amplifying a fragment of the Mtb rpoB gene at various cycle numbers was tested using wild type rpoB
sensors.

The maximum S/B of 7.82 achieved with 50 cycles led us to select this as the optimum
cycle number. Figure 10 indicates a single rep, however further experiments have confirmed our
findings.
SNP Analysis
Strain Typing
We next attempted to utilize the ability of binary DNAzyme sensors to detect SNPs for
molecular strain typing of Mtb. Based on a SNP-based typing algorithm proposed by Homolka
et al (2012), we designed sensors to detect the WT and mutant variants of the G455C SNP in the
gene rv0557 which distinguishes the Haarlem from non-Haarlem lineage. In this initial proof of
principle experiment, the two sensor pairs were tested against synthetic analytes representing the
Haarlem and non-Haarlem sequence at this site.
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Figure 12: Haarlem Vs. NonHaarlem Sensor Specificity. Both Haarlem and NonHaarlem fluorescent sensors
were tested using their matched and mismatched analyte respectively. These sensors targeted a GC mutation of
the 455th nucleotide of the rv0557 gene.

Both Haarlem and NonHaarlem sensors showed excellent specificity against synthetic
analytes, with a specificity ratio of 3.14 and 3.39 in one rep. These results combined with our
data showing binary DNAzyme detection of PCR amplicons suggest a PCR-based binary
DNAzyme assay would be effective for strain typing Mtb from these two distinct lineages.
Drug Resistance Analysis
Sensors to detect wild type rpoB gene were developed and tested against wild type and
mutant analyte.

The sensors designed detect wild type sequence which would indicate

susceptibility to Rif. This means that a loss of signal would indicate the presence of a drug
resistant mutant. A wild type sensor was chosen because the loss of signal would occur for any
mutation to the section of the rpoB gene being amplified, as opposed to detecting just one of
three possible nucleotides which would confer drug resistance.
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Figure 13: Specificity of rpoB Sensors using Wild-Type and Mutant Synthetic Analyte. Specificity was
determined using both matched (wild type) and mismatched (drug resistant) synthetic analyte. This was performed
in triplicate.

Using synthetic analyte the wild type sensors showed an acceptable level of specificity,
with a specificity ratio of 2.67. The matched analyte resulted in a S/B ratio of 3.33 while a
mismatched analyte containing the C526G mutation resulted in a signal of 1.25. Because the
rpoB gene is present in low copy number, primers were designed to amplify a 250 base pair
fragment of the gene containing the 81 base pair hot spot region. The specificity of the wild type
binary DNAzyme sensors were then determined using the PCR sample produced from both wild
type and Rif resistant BCG DNA. This DNA was generated from artificially selecting an rpoB
mutation in a strand of BCG within the lab, while the sequence was confirmed by independent
sequencing.
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Figure 14: rpoB Wild-Type Sensor Specificity using PCR Product. Specificity was determined using rpoB wild
type sensors after amplification using CDC1551 WT DNA and artificially selected Rif resistant BCG DNA. This
was performed in triplicate.

The specificity value of the wild type rpoB sensors using PCR product decreased to a
2.58, still indicating efficient discrimination between drug susceptible and drug resistant
variation of Mtb.
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Future Works
With these experiments, we have shown that binary DNAzyme sensors can be designed
to efficiently detect and characterize different species of pathogenic mycobacterium.

The

development of visual sensors also results in the generation of an assay which can translate into
POC diagnostics due to the ease of reading the output. We are currently testing out other
peroxidase substrate molecules which can potentially be used instead of DAB and produce an
even greater absorbance output. We also plan on testing other methods of detection such as a
384 well filter bottom plate, allowing the colored substrate molecule to be condensed into the
well and result in a stronger visual output. This would also be an alternative to using a plate
reader, eliminating the need for expensive equipment.
The characterization of the rpoB gene is vital in determining drug resistance or
susceptibility towards Rif, a first line drug used to treat Mtb. Because of the development of
MDR-Tb and XDR-Tb, it is necessary to design and test sensors which can characterize
resistance to additional antibiotics including Inh and FQs. We have currently developed primers
to amplify regions of the inhA, katG and gyrA genes, which can be combined with the rpoB
primers in one PCR reaction. This should allow the generation of a multiplex PCR product
which can be subjected to multiple binary DNAzyme assays to elucidate drug resistance
characterization to many different drugs.
In an effort to eliminate the need for a thermal cycler, we are currently testing isothermal
amplification techniques such as Loop Mediated Isothermal Amplification (LAMP). LAMP
utilizes 6 primers that recognize 6 distinct regions of DNA in a target sequence and results in the
generation of concatemeric stem loop DNA structures, all linked together with the same target
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sequence [127]. The elimination of a thermal cycler greatly increases the possibility that an
assay combining LAMP and the binary DNAzyme can directly translate into an efficient POC
diagnostics.
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Summary
The detection and differentiation of pathogenic mycobacterium is essential in diagnosis
and treatment of the disease. Early diagnosis results in higher survival rates among patients,
however current methods of diagnostics can be unreliable and expensive. We have shown that
sensors developed to detect Mabs are able to detect low quantities of total RNA and synthetic
analyte and are efficiently able to differentiate between Mabs and Mtb. We also designed
sensors to detect Mabs with a visual output, eliminating the need for a plate reader and
successfully advancing the development of a POC diagnostic test for the detection of pathogenic
mycobacteria.
SNP characterization in Mtb allows for the elucidation of a variety of molecular
characteristics of the individual strain, such as lineage and drug resistance profile. We were able
to successfully design sensors which were sensitive enough to differentiate between two strains
with a single residue difference. These sensors efficiently discriminate between two different
lineages of Mtb, allowing for effective strain typing without the need for whole genome
sequencing.
Characterization of drug resistance is of vital importance when treating an Mtb infection,
and determining drug susceptibility is vital for determining the course of treatment. We were
able to show that binary DNAzyme sensors were able to efficiently differentiate between Rif
susceptible and Rif resistant Mtb. We also showed that PCR amplification may be necessary in
characterizing SNPs found in genes which are present in low copy number, and the symmetric
PCR is effectively able to amplify a large enough quantity of amplicons to reliably detect with
DNAzyme sensor. We also showed that a binary DNAzyme sensor is still efficiently able to
37

differentiate between the different SNPs when using PCR amplicons as the analyte. Overall,
these experiments make ways to facilitate better treatment of TB by providing a novel platform
for POC detection.

We have shown that the binary DNAzyme platform is a promising

technology to fill this urgent need.
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Appendix
Fluorescent Sensors
Substrate: MzF

5’- AAGGTT-FAM-TCCTCguCCCTGGGCA-BHQ

Sensor

Adaptor Strand A
Adaptor Strand B (WT specific)
k2 (A1_rpoB_526_WT)
k1 (B1_rpoB_526_WT)
5’5’TGCCCAGGGAGGCTAGCTCCGACAGCGGGTT CGCTTGTGGGTCAAACAACGAGAGGAAACCTT
GTTCTGGTCC
Sequence
5’- GGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCG

rpoB Sensor

Analyte
k3
(rpoB_526_WT_CA
C)
MT
K3
- 5’- GGACCAGAACAACCCGCTGTCGGGGTTGACCTACAAGCG
DN (rpoB_526_MT
_TAC)
Sensor
Mabs 23S Sensor
Analyte
23S_M_abs-1

Adaptor Strand A
Adaptor Strand B
23S_M_abs_1a
23S_M_abs_1b
5’5’TGCCCAGGGAGGCTAGCTCAAGTCCGGTCAC GTGCGACCCACTCACGCTTGGGCCGACAACGA
CAAGCGAGGT
GAGGAAACCTT
Sequence
5’- ACCTCGCTTGGTGACCGGACTTGCTCCGTGAGCTGAACGAGGTCGTCGCAG
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Sensor

Adaptor Strand A
Adaptor Strand B
16S_M_abs_1a
16S_M_abs_1b
Mabs 16S 5’5’Sensor
TGCCCAGGGAGGCTAGCT
CAAAGCTTTGCACCACTCACCA
TGAAGTGTGTGGTCCTATCCGG
ACAACGAGAGGAAACCTT
Analyte
Sequence
16S_M_a 5’-CCG GAT AGG ACC ACA CAC TTC ATG GTG AGT GGT GCA AAG CTT TTG
bs-1
Sensor

Adaptor Strand A
Adaptor Strand B
tm_Mabs_1a
tm_Mabs_1b
Mabs TM 5’5’Sensor
TGCCCAGGGAGGCTAGCT
GTTTGATGTCCCGGTGGCCTCCGC
GGCCGAAGCCACCGGTTGATCCCG
ACAACGAGAGGAAACCTT
Analyte
Sequence
tm_M_ab 5’-GCGGGATCAACCGGTGGCTTCGGCCGCGGAGGCCACCGGGACATCAAC
Sensor

Adaptor Strand A
Adaptor Strand B
23S_Mtb_1a
23S_Mtb_1b
Mtb 23s 5’5’Sensor
TCGCCAGGGAGGCTAGCTCAAGGGTGTTCACGAT CTGCGACCGGATCCCGCTCCCACCGACAACGAGAG
ATTCCGGT
GAAACCTT
Analyte
Sequence
23S_Mtb- 5’-ACCGGAATATCGTGAACACCCTTGCGGTGGGAGCGGGATCCGGTCGCAG
1
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Sensor

Adaptor Strand A
Adaptor Strand B
nonHaarlem_455_G>T A1_fl
Haarlem_455_T B1 fl
Rv0557 Haarlem 5’5’Sensor
CTGTGGACGGCGCCAGAGTGCGGTCACAACGAGAGG TGCCCAGGGAGGCTAGCTAGCCAGGGGA
AAACCTT
TGCAA
Analyte
Sequence
Haarlem_455_C
5’- CCACTTGCATCCCCTGGCTGACCGCACTCTGGCGCCGTCCACAGCGAC
Sensor

Adaptor Strand A
Adaptor Strand B
nonHaarlem_455_G>T A1_fl
nonHaarlem_455_G_WT_B1_fl
Rv0557
Non- 5’5’Haarlem Sensor
CTGTGGACGGCGCCAGAGTGCGGTCACAACGAGAGG TGCCCAGGGAGGCTAGCTAGCCAGGCGA
AAACCTT
TGCCA
Analyte
Sequence
nonHaarlem_455 5’- CCACTTGCATCGCCTGGCTGACCGCACTCTGGCGCCGTCCACAGCGAC
_G-WT
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Visual Sensors
Substrate: IPDZ

5‘- GGG TAG GGC GGG TTG GGT TC rG rU CC ATG AGC AACTCG CCC

Sensor

Adaptor Strand A
23S_M_abs_1a_vis
5’GTTGCTCATGGAGGCTAGCTCAAGTCCGGTCA
CCAAGCGA

Adaptor Strand B
23S_M_abs_1b_vis
5’GTTTGATGTCCCGGTGGCCTCCGC
ACAACGAGAACCCAACC

Adaptor Strand A
16S_M_abs_1a_vis
5’GTTGCTCATGGAGGCTAGCTTGAAGTGTGTGG
TCCTATCCGG

Adaptor Strand B
16S_M_abs_1b_vis
5’CAAAGCTTTGCACCACTCACCAAC
AACGAGAACCCAACC

Adaptor Strand A
tm_Mabs_1a_vis
5’Mabs TM Visual Sensor
GTTGCTCATGGAGGCTAGCTGGCCGAAGCCAC
CGGTTGATCCCG
Note: Same Analytes are used as Fluorescent Assay

Adaptor Strand B
tm_Mabs_1b_vis
5’GTTTGATGTCCCGGTGGCCTCCGC
ACAACGAGAACCCAACC

Mabs 23S Visual Sensor

Sensor
Mabs 16S Visual Sensor

Sensor

Primers
Primers
Locus
rpoB

Primer
rpoB_sym200_F
rpoB_sym200_R

Sequence
5’- GTCGCCGCGATCAAGGAGTT
5’- CCCTCAGGGGTTTCGATCGGG
43

Locus
23S rRNA Mtb

Primer
Sequence
TB23S_aPCR_F
5’- GAACTCGGCAAAATGCCCCCGTAA
Tb23s_aPCR_R (For 5’- TTCGTGCAGGTCGGAACTTACCCCGACAAGG
LATE-PCR)
23SR_sym
5’- TTCGTGCAGGTCGGAACTTACCCG
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